Applicants: Graham P. Allaway et al.
Serial No.: 09/888,938
Filed: June 25, 2001
Exhibit 3

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-51. (Canceled)

52. (New) A method of inhibiting HIV-1 infection of a CD4+ cell in a subject which comprises administering to the subject a first compound which is a monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor; and (b) administering to the subject a second compound which is T-20 having the amino-acid sequence set forth in SEQ ID NO:1, so as to thereby inhibit HIV-1 infection of the CD4+ cell in the subject.

53. (New) The method of claim 52, wherein the first and second compounds are administered to the subject separately.

54. (New) The method of claim 52, wherein the first and second compounds are administered to the subject simultaneously.

55. (New) The method of claim 52, wherein the first and second compounds are administered to the subject at different times.

56. (New) The method of claim 55, wherein the first compound is administered to the subject following the administration of the second compound.

57. (New) The method of claim 52, wherein the first and second compounds are administered to the subject by different routes of administration.

58. (New) The method of claim 52, wherein the PA14 antibody or portion thereof is a humanized antibody or portion thereof.

59. (New) The method of claim 52, wherein the PA14 antibody or portion thereof is a chimeric antibody or portion thereof.

60. (New) The method of claim 52, wherein the relative mass ratio of the first compound to the second compound ranges from about 100:1 to about 1:100.

61. (New) A method of inhibiting HIV-1 infection of a CD4+ cell in a subject which comprises (a) administering to the subject a first compound which is a monoclonal antibody PA14 (produced by hybridoma PA14 having ATCC Accession No. HB-12610) or a portion thereof which binds to a CCR5 receptor; (b) administering to the subject a second compound which is a CD4-IgG2 chimeric heterotetramer comprising two heavy chains and two light chains, wherein the heavy chains are encoded by expression vector CD4-IgG2HC-pRcCMV having ATCC Accession No. 75193 and the light chains are encoded by expression vector CD4-kLC-pRcCMV having ATCC Accession No. 75194; and (c) administering to the subject a third compound which is T-20 having the amino-acid sequence set forth in SEQ ID NO:1, so as to thereby inhibit HIV-1 infection of the CD4+ cell.

62. (New) The method of claim 61, wherein the first and second compounds are administered to the subject separately.

63. (New) The method of claim 61, wherein the compounds are administered to the subject simultaneously.

64. (New) The method of claim 61, wherein the compounds are administered to the subject at different times.

65. (New) The method of claim 64, wherein the first compound is administered to the subject following the administration of

the third compound.

66. (New) The method of claim 64, wherein the first and second compounds are administered to the subject following the administration of the third compound.

67. (New) The method of claim 61, wherein the compounds are administered to the subject by different routes of administration.

68. (New) The method of claim 61, wherein the PA14 antibody or portion thereof is a humanized antibody or portion thereof.

69. (New) The method of claim 61, wherein the PA14 antibody or portion thereof is a chimeric antibody or portion thereof.

70. (New) The method of claim 61, wherein the relative mass ratio of any two of the compounds of (a)-(c) ranges from about 100:1 to about 1:100.